Biocon seeking rich partner for insulin pill development

Diabetes patients currently inject their insulin, of course. But India's Biocon sees opportunity in developing an oral insulin pill, despite a late-stage clinical trial setback this year for its IN-105 oral insulin treatment. Biocon is in advance discussions with potential partners to continue the pill's development, Reuters is reporting, with potential tweaks in design of the trial protocol. Rumored potential partners include Novo Nordisk ($NVO) and Eli Lilly ($LLY). Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.